Moderna and Merck have developed a personalized cancer vaccine that has successfully passed a phase 3 clinical trial and could generate annual sales of up to 54 billion dollars, surpassing the world's best-selling drug, Keytruda. #vacunacancer #tratamientospersonalizados #pharma (translated)













